Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings

Astellas Pharma is seeking approval for eye treatment Izervay in Japan and Europe, a bid to expand sales to counter a potential revenue drop for its top cancer medicine. https://www.japantimes.co.jp/business/2024/06/11/companies/astellas-eye-drug-japan-approval/ #business #companies #astellas #pharmaceuticals #medicine

GSK raises profit outlook on strong vaccine, HIV drug sales—Pfizer beats Q1 forecast despite 20% revenue drop, cuts four pipeline programs —Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal--http://bit.ly/w28kSd #earnings #gsk #pfizer #hiv #vaccines #celltherapy #astellas #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

#Astellas #καρκίνος_προστάτη Καρκίνος του προστάτη: Εκστρατεία ενημέρωσης και ευαισθητοποίησης από την Astellas  https://www.zougla.gr/zougla-newsroom/karkinos-tou-prostati-ekstrateia-enimerosis-kai-evaisthitopoiisis-apo-tin-astellas/?utm_source=dlvr.it&utm_medium=mastodon

Japanese Ambassador to China Kenji Kanasugi on Tuesday met with a Japanese employee of Astellas Pharma who has been detained by Chinese authorities on suspicion of espionage, diplomatic sources said. https://www.japantimes.co.jp/news/2024/03/26/japan/detained-astellas-worker-envoy-meet/ #japan #china #astellas #espionage #chinajapanrelations

GSK buying Aiolos for $1.4B to boost asthma pipeline —Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals— FDA declines to approve Astellas' gastric cancer drug --http://bit.ly/w28kSd #gsk #asthma #mergersandacquisitions #bristolmyerssquibb #fda #gastriccancer #astellas #jpmhc24 #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

After a record run, fewer biotechs are going public-- Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer— 8 medtech trends to watch in 2024 --http://bit.ly/w28kSd #ipos #merck #astellas #pfizer #bladdercancer #medtech #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field-- Biopharma’s top 5 IPOs of 2023 so far --Astellas builds case for menopause drug fezolinetant http://bit.ly/w28kSd #abbvie #mergersandacquisitions #immunogen #ipos #menopause #astellas #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff -- Vertex, CRISPR win world’s first approval for CRISPR-edited therapy from UK --BMS gets US approval for ROS1 lung cancer drug Augtyro-- See more on our front page news http://bit.ly/w28kSd #astellas #vertexpharma #crispr #geneediting #bristolmyerssquibb #lungcancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer-- BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application --Amazon will start delivering prescriptions by drone -- See more on our front page news http://bit.ly/w28kSd #seagen #astellas #merck #keytruda #esmo #bladdercancer #als #fda #amazon #drones #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma